Yes, but you should carry the prescription or a letter from your prescriber confirming the need for an unlicensed medication. Some countries may require additional documentation at customs.
Contact your prescriber promptly. An acute worsening may signal an unrelated vestibular event or a need to reassess the treatment plan.
All strengths contain the same active molecule and are absorbed similarly; the difference lies only in the total dose delivered per tablet.
Caution is advised. While betahistine can cause mild vasodilation, it may provoke blood pressure fluctuations in patients with uncontrolled hypertension or coronary artery disease. Discuss risks with your doctor.
Concurrent use may reduce the effectiveness of betahistine because antihistamines block H₁ receptors. Your physician may adjust the timing or choose alternative therapies.
Typical tablet excipients include lactose, microcrystalline cellulose, and magnesium stearate, but exact formulations can vary between manufacturers. Check the product’s patient information leaflet for specifics.
No direct pharmacokinetic interaction is reported, but both drugs can affect blood pressure; monitor cardiovascular status if you have underlying hypertension.
Duration is individualized. Some patients achieve stable control within months, while others require long-term maintenance. Regular review with your ENT specialist or neurologist is essential.
Betahistine is generally supplied as an unlicensed product; pharmacies may compound it or source it from overseas suppliers under a special prescription. No MHRA-approved generic exists domestically.
Betahistine Dihydrochloride is the active ingredient in the pill formulation marketed under the name Betahistine. It belongs to both the digestive health and neurology therapeutic areas because of its effects on inner-ear microcirculation and its influence on histamine pathways that can affect gastrointestinal function.
In the United Kingdom, Betavist® and other betahistine products do not have a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). The medication may only be obtained through a special prescription (e.g., a ‘unlicensed medicine’ supply) when a prescriber judges that the benefit outweighs the risk and no authorised alternative is suitable.
Betahistine is a histamine analogue that acts as a weak agonist at histamine H₁ receptors and a strong antagonist at histamine H₃ receptors.
The combined effect reduces the frequency and intensity of vertigo attacks and may alleviate associated nausea. Because histamine also modulates gastric secretions, betahistine can modestly influence digestive processes, though this is not its primary therapeutic purpose.
Onset of action is usually observed within a few days of starting therapy, with peak symptom control often achieved after 2-4 weeks of consistent dosing.
Betahistine is not licensed in the UK for any indication. However, in countries where it is authorised (e.g., several European nations, Australia, and parts of Asia), the medication is indicated for:
Because UK prescribing must follow local regulatory status, clinicians who choose to prescribe betahistine do so off-label, relying on international clinical experience and individual patient assessment.
These uses are not approved by the MHRA, and any off-label application should be undertaken only under direct supervision of a qualified healthcare professional.
These effects are usually self-limiting and do not require discontinuation unless they become bothersome.
| Interaction Level | Drugs/Classes | Reason | |-||--| | Major | Antihistamines (H₁ blockers) such as diphenhydramine | Opposing mechanisms may reduce betahistine efficacy. | | Moderate | CYP2D6 substrates (e.g., metoprolol, codeine) | Betahistine is minimally metabolised by CYP2D6; inhibition can modestly raise betahistine levels. | | Moderate | Anticholinergic agents (e.g., scopolamine) | May blunt vestibular compensation benefits. |
Patients should provide a complete medication list, including over-the-counter products and herbal supplements, to their prescriber.
| Strength | Typical Regimen* | |-|| | 8 mg tablet | 8 mg three times daily (total 24 mg) | | 16 mg tablet | 16 mg twice daily (total 32 mg) | | 24 mg tablet | 24 mg twice daily (total 48 mg) |
*These regimens reflect common practice in countries where betahistine is licensed. In the UK, the prescribing clinician must individualise the dose based on symptom severity, renal function, and tolerability.
Betahistine does not usually require tapering. However, abruptly stopping therapy may lead to a rebound of vertigo symptoms in some patients. Discuss any plan to discontinue with a healthcare professional.
This article provides educational information about Betahistine and is not a substitute for professional medical advice. Treatment decisions, including the use of unlicensed or off-label medications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
